Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ATNX

Athenex (ATNX) Stock Price, News & Analysis

Athenex logo

About Athenex Stock (NASDAQ:ATNX)

Key Stats

Today's Range
N/A
50-Day Range
$0.20
$1.52
52-Week Range
N/A
Volume
1.88 million shs
Average Volume
194,316 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Athenex Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
4th Percentile Overall Score

ATNX MarketRank™: 

Athenex scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Athenex.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for ATNX.
  • Dividend Yield

    Athenex does not currently pay a dividend.

  • Dividend Growth

    Athenex does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ATNX.
  • Search Interest

    17 people have searched for ATNX on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Athenex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Athenex is held by insiders.

  • Percentage Held by Institutions

    Only 30.48% of the stock of Athenex is held by institutions.

  • Read more about Athenex's insider trading history.
Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Athenex (NASDAQ: ATNX)
See More Headlines

ATNX Stock Analysis - Frequently Asked Questions

Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%.

Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

Last Earnings
11/04/2021
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
652
Year Founded
N/A

Profitability

Net Income
$-103,430,000.00
Pretax Margin
-95.92%

Debt

Sales & Book Value

Annual Sales
$102.82 million
Book Value
($3.07) per share

Miscellaneous

Free Float
7,866,000
Market Cap
$1.76 million
Optionable
Optionable
Beta
1.36
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ATNX) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners